Death receptor 5 (DR5) is a promising target for antitumor therapy due to its high expression on different tumor cells. Resistance of various tumor cells against TRAIL, a natural ligand for the death receptors, reduces its therapeutic potential and prompts the search for novel agonists at these receptors. Previous screening across the combinatorial peptide library yielded a peptide sequence KVVLTHR that specifically binds DR5. Incorporation of this sequence into TNFα resulted in binding DR5 with mutant protein TNFα-mut and appearance of cytotoxicity against lymphoma cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS, Sethi G. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp. Biol. Med. (Maywood). 2015;240(6):760-773.
Kiraz Y, Adan A, Kartal Yandim M, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumor Biol. 2016;37(7):8471-8486.
Naoum GE, Buchsbaum DJ, Tawadros F, Farooqi A, Arafat WO. Journey of TRAIL from bench to bedside and its potential role in immuno-oncology. Oncol. Rev. 2017;11(1):332. doi: https://doi.org/10.4081/oncol.2017.332.
Park HH, Lo YC, Lin SC, Wang L, Yang JK, Wu H. The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu. Rev. Immunol. 2007;25:561-586.
Tummers B, Green DR. Caspase-8: regulating life and death. Immunol. Rev. 2017;277(1):76-89.
Ukrainskaya VM, Stepanov AV, Belogurov AA Jr, Gabibov AG. Combinatorial screening of peptides, specific ligands of death receptor DR5. Bull. Exp. Biol. Med. 2017;163(3):381-384.
Van Ostade X, Tavernier J, Prangé T, Fiers W. Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. EMBO J. 1991;10(4):827-836.
Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002;7(5):449-459.
Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 2008;27(48):6207-6215.
Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol. Sin. 2008;29(11):1275-1288.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 165, No. 3, pp. 364-367, March, 2018
Rights and permissions
About this article
Cite this article
Ukrainskaya, V.M., Bobik, T.V., Argentova-Stevens, A. et al. Directed Change in TNFα Specificity to Create DR5 Antagonists. Bull Exp Biol Med 165, 386–389 (2018). https://doi.org/10.1007/s10517-018-4176-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-018-4176-9